Arch Oncology, Inc
4320 Forest Park Avenue
About Arch Oncology, Inc
Arch Oncology is an immuno-oncology company developing anti-CD47 antibodies for the treatment of cancer. Anti-CD47 therapies represent a new class of checkpoint inhibitors that bridge the innate and adaptive immune systems to attack cancer. Arch Oncology has developed a functionally diverse antibody platform and is advancing a novel anti-CD47 antibody to the clinic that not only acts as an immune checkpoint inhibitor, but also selectively kills tumor cells (non ADCC). The team is a highly motivated group of experienced scientists and emphasizes a collaborative approach. Arch Oncology is funded by top-quality venture capital investors and is advancing its lead mAb to the clinic currently.
7 articles with Arch Oncology, Inc
Drew Dennison is Managing Director at Lightchain Capital, LLC, the family office for Scottrade Founder and former Chief Executive Officer Rodger Riney.
5/24/2019Biopharma companies from across the globe strengthen their leadership teams with key executive appointments.
Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced the appointment of Kirk Christoffersen as Chief Business Officer.
Arch Oncology to Present Preclinical Data on Highly-Differentiated Anti-CD47 Antibody AO-176 at the AACR Annual Meeting 2019
Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 therapies for cancer, today announced the presentation of two posters at the American Association for Cancer Research (AACR) Annual Meeting to be held March 29 – April 3, 2019 in Atlanta, GA.
St. Louis, Missouri is one of the fastest-growing and top-ranked emerging life sciences markets in the U.S., ranking sixth in a recent CBRE Research report.
Financing to Advance Lead Anti-CD47 Antibody AO-176 in Ongoing Phase 1 Clinical Trial and Pipeline
Arch Oncology Announces First Patient Dosed in Phase 1 Clinical Trial of AO-176, an Anti-CD47 Antibody with a Best-in-Class Profile
Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of next-generation anti-CD47 antibody therapies for cancer, today announced the initiation of a new Phase 1 clinical trial of AO-176 in select solid tumors with the first patient dosed.